Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05885607 · ClinicalTrials.gov registry record
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
A clinical trial, sponsored by University of Pennsylvania.
- Active
- Registry status
- 40
- Enrollment target
NCT05885607: Active study, sponsored by University of Pennsylvania.
NCT05885607 is a clinical trial that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05885607 is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 40 participants
- Enrollment target
Study Summary
The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors. The main question it aims to answer is: * What are the impacts of SGLT2 inhibition on systemic metabolomic and proteomic profiles? Participants will be asked to do the following before and after being prescribed a SGLT2i. * Six-minute walk testd * Calf MRI with plantar flexion exercise * Blood sample collection
Primary Outcome
We will measure changes in venous concentrations of metabolic substrates and intermediates, along with circulating proteomic regulators using both targeted and untargeted surveys. SGLT2i has been shown to impact glucose, fatty acid, and ketone metabolism.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2027-06-30 |
What the registry record for NCT05885607 still lists
NCT05885607 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05885607 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05885607 about?
NCT05885607 is a clinical study titled "Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure". The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors. The main question it aims to answer is: * What are the impacts of SGLT2 inhibition on systemic metabolomic and ...
What is the current status of trial NCT05885607?
This trial is currently active not recruiting. The enrollment target is 40 participants. The study started on 2023-06-27. Estimated completion is 2027-06-30.
Who is sponsoring clinical trial NCT05885607?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI